Search
Clinician Ordering Portal
In this case, a more accurate assessment of the state of disease was attained through 40-GEP testing. Traditional staging methods, including AJCC8 and BWH, overestimated our patient’s risk profile. More research needs to be completed surrounding gene testing and metastatic risk. Our goal with this case is to contribute to the growing body of literature surrounding the use of gene expression profile testing in cutaneous cancer.
Scientific evidence
The tissue systems pathology test outperforms pathology review in risk-stratifying patients with low-grade dysplasia
Nov 2023
This study aimed to compare the risk stratification performance of the TissueCypher test vs benchmarks of generalist and expert pathology.
Publication: Gastroenterology
An Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients with Barrett's Esophagus
Nov 2023
Management guided by the TissueCypher test can standardize care plans by increasing the early detection of progressors who can receive therapeutic interventions, while also increasing the percentage of nonprogressors who can avoid unnecessary therapy and be managed by surveillance alone.
Publication: American Journal of Gastroenterology
A Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients with Barrett’s Esophagus
Nov 2023
This study evaluated the predictive performance of TissueCypher versus current clinicopathologic variables in a multi-center cohort of BE patients.
Publication: Clinical and Translational Gastroenterology
Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi center performance cohort of cutaneous melanocytic neoplasms
Oct 2023
Publication: Poster, presented at the 2023 ASDP Annual Meeting
The tissue systems pathology test predicts risk of progression in Medicare-eligible patients with Barrett’s esophagus
Oct 2023
TissueCypher risk-stratifies BE patients ≥ 65 years old independently of clinicopathologic variables and has significantly higher sensitivity for detection of progressors than pathology diagnosis of LGD.
Publication: Poster presentation (S599) at ACG 2023, Vancouver
The tissue systems pathology test objectively risk-stratifies patients with Barrett’s esophagus: a multicenter US clinical experience study
Oct 2023
TissueCypher risk-stratifies BE patients ≥ 65 years old independently of clinicopathologic variables and has significantly higher sensitivity for detection of progressors than pathology diagnosis of LGD.
Publication: Poster presentation (S600) at ACG 2023, Vancouver
40-gene expression profile representative of metastatic risk of squamous cell carcinoma in a Mohs surgical patient
Oct 2023
Publication: Cureus
Gene expression differences identified in skin samples of early-stage mycosis fungoides, atopic dermatitis, and psoriasis
Oct 2023
Publication: Poster, presented at the 2023 Fall Clinical Dermatology Conference®, Las Vegas, Nevada, October 19-22, 2023
The integrated i31-GEP test outperforms the MSKCC nomogram at predicting SLN status in melanoma patients
Sep 2023
This study evaluates the performance of DecisionDx-Melanoma and the MSKCC nomogram in a head-to-head study in 465 patients withT1 or T2 tumors and known SLN status
Publication: Anticancer Research
A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center
Sep 2023
TissueCypher demonstrated clinical utility in NDBE patients by guiding risk-aligned upstaging of care and potential improved health outcomes in BE patients.
Publication: Poster presentation (61) at AFS 2023, Dallas
The importance of incorporating drug-drug interactions and lifestyle factors in pharmacogenomics-guided medication management for patients with major depressive disorder in a randomized controlled trial
Sep 2023
In this study, drug-drug interactions accounted for 32% of all IDgenetix-guided drug recommendations, and lifestyle factors accounted for 11%. Incorporating these non-genetic factors in IDgenetix testing significantly impacts the number of drug recommendations and improves remission rates in patients with moderate to severe depression.
Publication: Poster at Psych Congress 2023
The tissue systems pathology-9 test provides clinically-impactful risk stratification in patients with Barrett’s esophagus: clinical experience in a multicenter cohort
Aug 2023
This study evaluated the use of the validated, commercially-available tissue systems pathology test (TissueCypher, TSP-9) to risk-stratify BE patients in a large clinical practice cohort.
Publication: Diseases of the Esophagus